GetTopicDetailResponse(id=e95742114c0, topicName=基石藥業(yè), introduction=基石藥業(yè), content=null, image=null, comments=1, allHits=2234, url=https://h5.medsci.cn/topic?id=42114, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=84313, tagList=[TagDto(tagId=84313, tagName=基石藥業(yè))], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=889498, encodeId=ad85889498d4, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#輝瑞#</a>作為老牌制藥公司，在腫瘤領(lǐng)域都是經(jīng)典的老藥，在創(chuàng)新藥方面全面落伍，不管是靶向治療還是免疫治療時代，都沒有抓住機會。這次與<a href='/topic/show?id=e95742114c0' target=_blank style='color:#2F92EE;'>#基石藥業(yè)#</a>合作的PD-L1單抗<a href='/topic/show?id=9e52103953a4' target=_blank style='color:#2F92EE;'>#舒格利單抗#</a>，應(yīng)該是輝瑞在中國的一個契機, objectTitle=輝瑞投資基石藥業(yè)2億美元，獲得PD-L1大陸?yīng)毤疑虡I(yè)權(quán)利, objectType=article, longId=201425, objectId=e5ba20142593, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/image013.jpg, objectUrl=/article/show_article.do?id=e5ba20142593, replyNumber=0, likeNumber=513, createdTime=2020-09-30, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5ba20142593, moduleTitle=輝瑞投資基石藥業(yè)2億美元，獲得PD-L1大陸?yīng)毤疑虡I(yè)權(quán)利, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=e5ba20142593)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
